ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma

Oncogene

Volumn 33, Issue 20, 2014, Pages 2665-2673

  Busch, S E ^a,b   Moser, R D ^a   Gurley, K E ^a   Kelly Spratt, K S ^a   Liggitt, H D ^b   Kemp, C J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ethyl carbamate; metastasis; p14ARF; p19Arf

Indexed keywords

ARF PROTEIN; DNA; PROTEIN P21; PROTEIN P53; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARF GENE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; GENE LOCATION; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; METASTASIS; MORBIDITY; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DEPLETION; PULMONARY SARCOMATOID CARCINOMA; TUMOR INVASION; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANIMALIA; MUS;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA DAMAGE; GENES, RAS; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901195889     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.208     Document Type: Article

References (60)

1. SEER Cancer Statistics Review, 1975-2008.National Cancer Institute: Bethesda, MD, USA. Available from http://seer.cancer.gov/csr/1975-2008/.
2. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075
3. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000. (Pubitemid 26006540
4. Sharpless NE. INK4a/ARF: A multifunctional tumor suppressor locus. Mutat Res 2005; 576: 22-38. (Pubitemid 40982680
5. Sherr CJ. Divorcing ARF and p53: An unsettled case. Nat Rev Cancer 2006; 6: 663-673
6. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. Tumour biology: Senescence in premalignant tumours. Nature 2005; 436: 642. (Pubitemid 41117258
7. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010; 468: 567-571
8. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA et al. Stage-specific sensitivity to p53 restoration During lung cancer progression. Nature 2010; 468: 572-575
9. Young NP, Jacks T. Tissue-specific p19Arf regulation Dictates the response to oncogenic K-ras. Proc Natl Acad Sci USA 2010; 107: 10184-10189
10. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65: 10280-10288. (Pubitemid 41743720
11. Wang Y, Zhang Z, Lubet RA, You M. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. Oncogene 2006; 25: 1277-1280
12. Tam AS, Devereux TR, Patel AC, Foley JF, Maronpot RR, Massey TE. Perturbations of the Ink4a/Arf gene locus in aflatoxin B1-induced mouse lung tumors. Carcinogenesis 2003; 24: 121-132. (Pubitemid 36196729
13. Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998; 17: 2779-2785. (Pubitemid 28554237
14. Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 1999; 18: 5843-5849. (Pubitemid 29520440
15. Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD et al. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 2001; 61: 5636-5643. (Pubitemid 32694951
16. Gao N, Hu YD, Cao XY, Zhou J, Cao SL. The exogenous wild-Type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines. J Cancer Res Clin Oncol 2001; 127: 359-367. (Pubitemid 32453678
17. Zhang W, Zhu J, Bai J, Jiang H, Liu F, Liu A et al. Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549. J Exp Clin Cancer Res 2010; 29: 74
18. Kamijo T, Bodner S, van De Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARFdeficient mice. Cancer Res 1999; 59: 2217-2222
19. Busch SE, Gurley KE, Moser RD, Kemp CJ. ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model. J Pathol 2012; 227: 298-305
20. Rogers S. Age of the host and other factors affecting the production with urethane of pulmonary adenomas in mice. J Exp Med 1951; 93: 427-449
21. Tannenbaum A, Maltoni C. Neoplastic response of various tissues to the administration of urethane. Cancer Res 1962; 22: 1105-1112
22. Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L et al. Review article: Pulmonary sarcomatoid carcinomas: A practical overview. Int J Surg Pathol 2010; 18: 103-120
23. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 1989; 86: 3070-3074. (Pubitemid 19129560
24. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-Activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999; 18: 664-674. (Pubitemid 29057251
25. Lavoie JN, Rivard N, L'Allemain G, Pouyssegur J. A temporal and biochemical link between growth factor-Activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res 1996; 2: 49-58
26. Robles AI, Rodriguez-Puebla ML, Glick AB, Trempus C, Hansen L, Sicinski P et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998; 12: 2469-2474. (Pubitemid 28406950
27. Lin AW, Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci USA 2001; 98: 5025-5030. (Pubitemid 32397076
28. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K et al. P53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935-944
29. Manenti G, Gariboldi M, Fiorino A, Zanesi N, Pierotti MA, Dragani TA. Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression. Cancer Res 1997; 57: 4164-4166. (Pubitemid 27413415
30. Zhang Z, Wang Y, Herzog CR, Liu G, Lee HW, DePinho RA et al. A strong candidate gene for the Papg1 locus on mouse chromosome 4 affecting lung tumor progression. Oncogene 2002; 21: 5960-5966. (Pubitemid 35007250
31. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001; 413: 86-91. (Pubitemid 32843493
32. Saporita AJ, Maggi Jr. LB, Apicelli AJ, Weber JD. Therapeutic targets in the ARF tumor suppressor pathway. Curr Med Chem 2007; 14: 1815-1827. (Pubitemid 47163401
33. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D et al. Classification of proliferative pulmonary lesions of the mouse: Recommendations of the mouse models of human cancers consortium. Cancer Res 2004; 64: 2307-2316. (Pubitemid 38523879
34. Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol 1996; 20: 277-285. (Pubitemid 26071508
35. Dacic S, Finkelstein SD, Sasatomi E, Swalsky PA, Yousem SA. Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. Am J Surg Pathol 2002; 26: 510-516. (Pubitemid 34280126
36. Debies MT, Gestl SA, Mathers JL, Mikse OR, Leonard TL, Moody SE et al. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/ p53 pathway lesions but not p16 Ink4a loss. J Clin Invest 2008; 118: 51-63
37. Cardiff RD. Epithelial to mesenchymal transition tumors: Fallacious or snail's pace?. Clin Cancer Res 2005; 11: 8534-8537
38. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF et al. Overexpression of mouse D-Type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559-1571. (Pubitemid 23234349
39. D'Amico M, Wu K, Fu M, Rao M, Albanese C, Russell RG et al. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements. Cancer Res 2004; 64: 4122-4130. (Pubitemid 38802414
40. Andrique L, Fauvin D, El Maassarani M, Colasson H, Vannier B, Seite P. ErbB3 (80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF. Cell Signal 2012; 24: 1074-1085
41. Aggarwal P, Lessie MD, Lin DI, Pontano L, Gladden AB, Nuskey B et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev 2007; 21: 2908-2922. (Pubitemid 350133439
42. Pontano LL, Diehl JA. Speeding through cell cycle roadblocks: Nuclear cyclin D1-dependent kinase and neoplastic transformation. Cell Div 2008; 3: 12
43. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation. Lung Cancer 2007; 55: 1-14. (Pubitemid 46038884
44. Normand G, Hemmati PG, Verdoodt B, von Haefen C, Wendt J, Guner D et al. p14ARF induces G2 cell cycle arrest in p53- And p21-deficient cells by downregulating p34cdc2 kinase activity. J Biol Chem 2005; 280: 7118-7130. (Pubitemid 40341268
45. Eymin B, Claverie P, Salon C, Leduc C, Col E, Brambilla E et al. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 2006; 26: 4339-4350. (Pubitemid 43788032
46. Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM. Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem 2005; 280: 18771-18781. (Pubitemid 41379578
47. di Tommaso A, Hagen J, Tompkins V, Muniz V, Dudakovic A, Kitzis A et al. Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Exp Cell Res 2009; 315: 1326-1335
48. Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A et al. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J Biol Chem 2007; 282: 1322-1333. (Pubitemid 47076587
49. Zeng Y, Kotake Y, Pei XH, Smith MD, Xiong Y. P53 binds to and is required for the repression of Arf tumor suppressor by HDAC and polycomb. Cancer Res 2011; 71: 2781-2792
50. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 2007; 26: 6896-6904. (Pubitemid 47609074
51. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006; 443: 214-217. (Pubitemid 44387609
52. Efeyan A, Garcia-Cao I, Herranz D, Velasco-Miguel S, Serrano M. Tumour biology: Policing of oncogene activity by p53. Nature 2006; 443: 159. (Pubitemid 44387596
53. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. P19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol 2004; 2: E242
54. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006; 13: 941-950
55. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622
56. Wang Y, Zhang Z, Kastens E, Lubet RA, You M. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: Differential chemopreventive effect of budesonide in wild-Type and mutant A/J mice. Cancer Res 2003; 63: 4389-4395. (Pubitemid 36951008
57. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659. (Pubitemid 27513656
58. Kelly-Spratt KS, Philipp-Staheli J, Gurley KE, Hoon-Kim K, Knoblaugh S, Kemp CJ. Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Krasdriven lung cancer. Oncogene 2009; 28: 3652-3662
59. Philipp-Staheli J, Kim KH, Payne SR, Gurley KE, Liggitt D, Longton G et al. Pathwayspecific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell 2002; 1: 355-368
60. Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-Activated kinases. Cancer Cell 2009; 16: 33-43